Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Mar;7(2):123-8.
doi: 10.1007/s11912-005-0038-5.

Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor

Emiliano Calvo  1 , Eric K Rowinsky
Affiliations
Review

Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor

Emiliano Calvo et al. Curr Oncol Rep. 2005 Mar.

Abstract

Preclinical and clinical studies consistently demonstrate the antitumor activity of the various monoclonal antibodies (mAbs) that block ligand binding to the extracellular domain of the epidermal growth factor receptor (EGFR). However, the objective antitumor activities of these agents are disproportionately lower than would be expected based on the high rates of expression, overexpression, and aberrations of EGFR in human malignancies, particularly carcinomas. Several technologic and clinical approaches are being explored to optimize the potency of these antibodies, such as humanization of the murine parent molecules, and conjugation and widening of the specificity of the mAb. Also, combined therapy with the different types of EGFR-interacting or other targeted agents may lead to a heightened potential. This review highlights the results of current approaches for improvement of the therapeutic indices of these agents.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Cancer Immunol Immunother. 2003 May;52(5):342-6 - PubMed
    1. J Nucl Med. 2002 May;43(5):693-713 - PubMed
    1. Cancer Treat Rev. 2004 May;30(3):255-68 - PubMed
    1. Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):210-5 - PubMed
    1. Hematol Oncol Clin North Am. 2002 Oct;16(5):1041-63 - PubMed

LinkOut - more resources